Bizengri won an FDA label expansion for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, backed by Phase I/II eNRGy data showing a 36.8% confirmed overall response rate in 19 evaluable patients. The single-arm study enrolled 22 patients, and the approval gives the HER2/HER3-directed bispecific antibody its third tumor indication while arriving more than five months ahead of the FDA goal date under the agency's national priority voucher pilot program.

Why It Matters To Oncology

• Cholangiocarcinoma has limited targeted options, and NRG1 fusions define a rare but actionable subset.

• The expansion builds on Bizengri's earlier accelerated approval in NRG1 fusion-positive Non-Small Cell Lung Cancer (NSCLC) and pancreatic adenocarcinoma, reinforcing a tumor-agnostic-style biomarker strategy across epithelial cancers.

• For drug discovery teams, the decision further validates HER2/HER3 pathway targeting with a bispecific antibody in fusion-driven disease.

The Financials

• Bizengri was originally developed by Merus and is now commercialized in the U.S. by Partner Therapeutics under a 2024 licensing deal.

• This is the seventh approval under the FDA's national priority voucher pilot, a program designed to compress review timelines for selected applications.

• The review finished more than five months early, a potentially meaningful advantage for launch timing in a rare oncology niche.

What They're Saying

• The FDA based the expansion on eNRGy trial results in previously treated patients with unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma.

• Among responders, duration of response ranged from 2.8 months to 12.9 months by blinded independent central review.

• The regimen is given as an intravenous infusion every two weeks until progression or unacceptable toxicity.

What's Next

• Clinicians will likely focus on broader genomic testing uptake in biliary tract cancers to identify the small population with NRG1 fusions.

• Investigators and developers will be watching for additional dataset maturation, including durability and real-world use across Bizengri's growing biomarker-defined indications.

• The approval may also sharpen interest in other fusion-driven solid tumor programs and in expedited FDA pathways that can accelerate rare cancer drug development.